Survival of Californian @entity1 with XXXX , 1994-1996: a population-based study.

@entity1 @entity43 @entity66 @entity5 @entity204
OBJECTIVE: The objective was to identify demographic, clinical, and provider characteristics that might influence @entity5 survival in a cohort of Northern California @entity1 using a population-based @entity5 registry. METHODS: We used California @entity5 Registry data to evaluate survival in 1051 Northern California @entity1 who were diagnosed with @entity43 between 1994 and 1996 and underwent a surgical procedure for their @entity5 . Chemotherapy data from the @entity5 registry were supplemented with a physician survey and medical record review. Database linkages with census and hospital discharge data provided socioeconomic and comorbidity measures. Kaplan-Meier method was used to generate survival curves and multivariate Cox proportional hazard models were used to evaluate the effect of different factors on survival. RESULTS: Crude 5-year survival was 82, 57, 28, and 10% for @entity1 with FIGO stage IC, II, III, and IV disease, respectively. Adverse survival was most strongly influenced by advanced stages III and IV with a hazards ratio ranging from 8 to 11.8 compared to stage @entity66 . Multivariate analysis also identified other adverse factors including high grade and other adverse histologies, age over 45, and rural location. Chemotherapy decreased the risk of @entity204 by 50% if the @entity1 had @entity5 . Medical comorbidity increased the risk of @entity204 by 40%. Survival was not influenced by race/ethnicity, socioeconomic status, physician specialty, or hospital characteristics. CONCLUSION: Advanced age remains an adverse prognostic factor even after adjustment for treatment and comorbidity factors. These results also suggest that there may be important regional differences in @entity43 survival.
